HomeCompareRVPHW vs DIVO

RVPHW vs DIVO: Dividend Comparison 2026

RVPHW yields 66666.67% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVPHW wins by $8.441837856534449e+24M in total portfolio value
10 years
RVPHW
RVPHW
● Live price
66666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.441837856534449e+24M
Annual income
$8,417,001,582,403,749,000,000,000,000,000.00
Full RVPHW calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — RVPHW vs DIVO

📍 RVPHW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVPHWDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVPHW + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVPHW pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVPHW
Annual income on $10K today (after 15% tax)
$5,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,154,451,345,043,187,000,000,000,000,000.00/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, RVPHW beats the other by $7,154,451,345,043,187,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVPHW + DIVO for your $10,000?

RVPHW: 50%DIVO: 50%
100% DIVO50/50100% RVPHW
Portfolio after 10yr
$4.2209189282672247e+24M
Annual income
$4,208,500,791,201,874,400,000,000,000,000.00/yr
Blended yield
99.71%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVPHW buys
0
DIVO buys
0
No recent congressional trades found for RVPHW or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVPHWDIVO
Forward yield66666.67%6.49%
Annual dividend / share$2.00$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.441837856534449e+24M$30.7K
Annual income after 10y$8,417,001,582,403,749,000,000,000,000,000.00$981.68
Total dividends collected$8.44020886744369e+24M$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: RVPHW vs DIVO ($10,000, DRIP)

YearRVPHW PortfolioRVPHW Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$6,677,367$6,666,666.67$11,349$649.42+$6.67MRVPHW
2$4,167,497,846$4,160,353,063.34$12,833$688.83+$4167.49MRVPHW
3$2,431,161,901,635$2,426,702,678,939.67$14,459$727.90+$2431161.89MRVPHW
4$1,325,636,209,022,888$1,323,034,865,788,139.00$16,238$766.49+$1325636209.01MRVPHW
5$675,632,775,263,916,700$674,214,344,520,262,300.00$18,179$804.47+$675632775263.90MRVPHW
6$321,867,481,182,444,260,000$321,144,554,112,911,900,000.00$20,293$841.71+$321867481182444.25MRVPHW
7$143,326,993,661,751,470,000,000$142,982,595,456,886,240,000,000.00$22,591$878.14+$143326993661751472.00MRVPHW
8$59,657,925,421,851,500,000,000,000$59,504,565,538,633,426,000,000,000.00$25,087$913.65+$59657925421851500544.00MRVPHW
9$23,211,471,150,187,795,000,000,000,000$23,147,637,169,986,416,000,000,000,000.00$27,791$948.18+$2.3211471150187796e+22MRVPHW
10$8,441,837,856,534,450,000,000,000,000,000$8,417,001,582,403,749,000,000,000,000,000.00$30,718$981.68+$8.441837856534449e+24MRVPHW

RVPHW vs DIVO: Complete Analysis 2026

RVPHWStock

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.

Full RVPHW Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this RVPHW vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVPHW vs SCHDRVPHW vs JEPIRVPHW vs ORVPHW vs KORVPHW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.